The American Gastroenterological Association has published new clinical guidelines for treating mild-to-moderate ulcerative colitis (UC), an inflammatory bowel disease (IBD). Mild-to-moderate UC, characterized by periods of disease activity followed by periods of remission, is defined by these symptoms:
- Fewer than four to six bowel movements per day
- Mild or moderate rectal bleeding
- Absence of symptoms like fever, fatigue, weight loss, or malaise
- Low, rather than high, levels of inflammatory activity
The new guidelines, published in Gastroenterology, focus on the use of oral and topical 5-aminosalicylates (5-ASA) medications (sulfasalazine, mesalamine, balsalazide, olsalazine), rectal corticosteroids, and oral budesonide (Entocort EC, Uceris). People with ulcerative colitis who don’t respond to these therapies may require a stronger medication regimen, but the new guidelines don’t address these treatments.
Sourced from: Gastroenterology